AstraZeneca Pharma India secured CDSCO approval to market Enhertu for an additional breast cancer indication. This expands its oncology portfolio by enabling first-line treatment for HER2-positive metastatic breast cancer patients, strengthening its market position.

AstraZeneca Pharma India Gains CDSCO Approval for Enhertu

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organization (CDSCO) on June 10, 2026, to import for sale and distribution of Trastuzumab deruxtecan (Enhertu) 100 mg/5mL vial for an additional indication.

What Just Happened

The CDSCO approval allows AstraZeneca to expand the use of its key oncology drug, Enhertu. It is now indicated for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, when used in combination with pertuzumab.

Why This Matters

This regulatory milestone significantly strengthens AstraZeneca Pharma India's oncology portfolio. Expanding the therapeutic utility of Enhertu increases the addressable patient population for HER2-positive breast cancer, driving potential revenue growth and reinforcing the company's commitment to cancer care.

Reader Takeaway

Positive regulatory win for Enhertu; monitoring commercial launch and any further requirements.

The Backstory

Trastuzumab deruxtecan (Enhertu) is a targeted therapy that has shown significant efficacy in treating HER2-positive cancers. This approval builds on its established use and broadens its application in earlier lines of treatment for metastatic breast cancer.

What Changes Now

The company can now market and distribute Enhertu for this specific new indication, subject to any applicable statutory approvals. This is a crucial step in leveraging the drug's full potential in the Indian market.

Risks to Watch

The marketing of the drug for this additional indication is subject to the receipt of related statutory approvals, if any, which could introduce delays.

Peer Comparison

As a significant player in the oncology segment, AstraZeneca competes with other pharmaceutical companies offering advanced cancer therapies. Approvals for expanded indications are critical for maintaining a competitive edge and expanding market share.

Context Metrics (Time-bound)

CDSCO approval received on June 10, 2026, for Trastuzumab deruxtecan (Enhertu).

What to Track Next

Investors should monitor announcements regarding the commercial launch strategy for Enhertu's new indication, sales performance, and any further regulatory updates or pipeline developments from AstraZeneca Pharma India.